GT200000017A - Procedimiento para la obtencion de derivados de 4-fenil-piridina. - Google Patents
Procedimiento para la obtencion de derivados de 4-fenil-piridina.Info
- Publication number
- GT200000017A GT200000017A GT200000017A GT200000017A GT200000017A GT 200000017 A GT200000017 A GT 200000017A GT 200000017 A GT200000017 A GT 200000017A GT 200000017 A GT200000017 A GT 200000017A GT 200000017 A GT200000017 A GT 200000017A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- salts
- present
- disorders
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99103504 | 1999-02-24 | ||
EP99123689 | 1999-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200000017A true GT200000017A (es) | 2001-08-15 |
Family
ID=26152908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200000017A GT200000017A (es) | 1999-02-24 | 2000-02-22 | Procedimiento para la obtencion de derivados de 4-fenil-piridina. |
Country Status (55)
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3979099A (en) * | 1998-05-11 | 1999-11-29 | Philadelphia Health & Education Corporation | (mct-1), a human oncogene |
NZ513322A (en) | 1999-02-24 | 2004-07-30 | F | Phenyl- and pyridinyl derivatives |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
TR200302077T4 (tr) * | 1999-11-29 | 2004-01-21 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
JP3938651B2 (ja) * | 2000-04-13 | 2007-06-27 | セントラル硝子株式会社 | 光学活性α−メチル−ビス−3、5−(トリフルオロメチル)ベンジルアミンの製造方法 |
ATE400556T1 (de) | 2000-07-14 | 2008-07-15 | Hoffmann La Roche | N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten |
TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
PT1349541E (pt) | 2000-12-14 | 2007-01-31 | Hoffmann La Roche | Matriz lipídica auto-emulsionante (selm) |
US6531597B2 (en) * | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
DE60220997T2 (de) * | 2001-03-27 | 2008-03-13 | Eisai R&D Management Co., Ltd. | N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält |
MXPA03009720A (es) * | 2001-04-23 | 2004-01-29 | Hoffmann La Roche | USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. |
ATE491474T1 (de) * | 2001-06-07 | 2011-01-15 | Sang Christine Dr | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
DK1427397T3 (da) * | 2001-09-10 | 2008-05-26 | Hoffmann La Roche | Olieagtige thixotrope formuleringer |
US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
WO2004026823A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
ATE443699T1 (de) * | 2002-12-06 | 2009-10-15 | Purdue Research Foundation | Pyridine zur behandlung von verletztemsäugetiernervengewebe |
US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
AU2004208483B8 (en) * | 2003-01-31 | 2008-04-03 | F. Hoffmann-La Roche Ag | Crystalline modifications of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lamda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
NZ544244A (en) * | 2003-07-03 | 2008-10-31 | Hoffmann La Roche | Dual NK1/NK3 antagonists for treating schizophrenia |
US7288658B2 (en) | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
ES2375134T3 (es) | 2003-07-30 | 2012-02-27 | Xenon Pharmaceuticals Inc. | Derivados de piperazina y su uso como agentes terapéuticos. |
BRPI0418939A (pt) * | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
CA2572645C (en) * | 2004-07-06 | 2011-01-18 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
KR100881240B1 (ko) * | 2004-07-06 | 2009-02-05 | 에프. 호프만-라 로슈 아게 | Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법 |
US20060030556A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
AR051094A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
JP4958785B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体およびステアロイル−CoAデサチュラーゼインヒビターとしてのそれらの使用 |
AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
CN101084211A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US20060135636A1 (en) * | 2004-11-15 | 2006-06-22 | Honeywell International Inc. | Isocyanate-based polymer foams with nano-scale materials |
EP1856052B1 (en) * | 2005-02-22 | 2009-09-02 | F.Hoffmann-La Roche Ag | Nk1 antagonists |
CA2599164A1 (en) * | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel pyridine derivatives as potassium ion channel openers |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
PL1863767T3 (pl) * | 2005-03-23 | 2009-08-31 | Helsinn Healthcare Sa | Metabolity antagonistów NK-1 do leczenia wymiotów |
WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
EP1912983B1 (en) * | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
CA2621564C (en) | 2005-09-09 | 2014-06-03 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
NZ566419A (en) | 2005-09-23 | 2010-03-26 | Hoffmann La Roche | Novel dosage formulation |
EP3696174A1 (en) * | 2005-11-08 | 2020-08-19 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7872022B2 (en) * | 2006-04-03 | 2011-01-18 | Hoffmann-La Roche Inc. | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety |
SI2674428T1 (sl) | 2006-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Modulatorji transporterjev atp-vezavne kasete |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CN101687842B (zh) | 2007-05-09 | 2013-03-06 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
LT2639223T (lt) * | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
EP2249650A4 (en) * | 2008-02-19 | 2012-01-11 | Glaxosmithkline Llc | ANILINOPYRIDINE AS A FAK HEMMER |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
IN2012DN01292A (US07585860-20090908-C00162.png) * | 2009-08-27 | 2015-06-05 | Glaxosmithkline Llc | |
ES2494015T3 (es) | 2009-11-18 | 2014-09-12 | Helsinn Healthcare Sa | Composiciones para tratar nauseas y vómitos de origen central |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
TW201143768A (en) * | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
WO2011127241A2 (en) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
RS54783B1 (sr) | 2010-04-07 | 2016-10-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline |
CN103038214B (zh) | 2010-04-22 | 2015-09-30 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
US20140155419A1 (en) * | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
EP2747560A4 (en) * | 2011-07-29 | 2015-02-25 | Tempero Pharmaceuticals Inc | CONNECTIONS AND METHODS |
CN105412110B (zh) | 2011-10-18 | 2018-05-25 | 赫尔森保健股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
ME02650B (me) | 2011-11-08 | 2017-06-20 | Vertex Pharma | Modulatori atp- vezujućih kasetnih transportera |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
KR20160078997A (ko) * | 2013-11-08 | 2016-07-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 카복시메틸피페리딘 유도체 |
KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
US20150315149A1 (en) * | 2014-05-05 | 2015-11-05 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
TWI649307B (zh) * | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
TW201613888A (en) | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
CN107110831B (zh) | 2014-11-18 | 2020-02-21 | 弗特克斯药品有限公司 | 进行高通量试验高效液相色谱的方法 |
DK3265087T3 (da) | 2015-03-04 | 2020-10-19 | Vanda Pharmaceuticals Inc | Fremgangsmåde til behandling med tradipitant |
CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | 成都欣捷高新技术开发有限公司 | 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法 |
US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
EP3388423B1 (en) * | 2015-12-07 | 2020-05-27 | Kissei Pharmaceutical Co., Ltd. | Nk1 receptor antagonist |
TWI773657B (zh) * | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CN106892864A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种奈妥皮坦游离碱的晶型a及其制备方法 |
CA3009325A1 (en) | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
EA201992414A1 (ru) | 2017-04-10 | 2020-03-16 | Чейс Терапьютикс Корпорейшн | Комбинация nk1-антагониста и способ лечения синуклеинопатий |
EP3645120A4 (en) | 2017-06-30 | 2021-03-24 | Chase Pharmaceuticals Corporation | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION |
CN109384712B (zh) * | 2017-08-14 | 2021-05-07 | 北京宽厚医药科技有限公司 | 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用 |
WO2019038656A1 (en) | 2017-08-21 | 2019-02-28 | Leiutis Pharmaceuticals Pvt, Ltd | NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY |
AU2019348001B2 (en) * | 2018-09-28 | 2023-09-21 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
US20220073467A1 (en) * | 2018-12-24 | 2022-03-10 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof |
CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
JP2023519570A (ja) | 2020-04-03 | 2023-05-11 | ネッレ セラピューティクス リミテッド | 新規使用 |
CN115697332A (zh) | 2020-06-02 | 2023-02-03 | 尼尔医疗有限公司 | 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂 |
EP4385500A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Fixed dose combination comprising netupitant and palonosetron |
EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1557420A (en) | 1977-03-10 | 1979-12-12 | Soc D Etudes Prod Chimique | Preparation of isobutyramide derivatives |
KR810001320B1 (ko) | 1977-03-17 | 1981-10-14 | 삐에르 위브 | 신규한 이소부티라미드류의 제조방법 |
KR810001697B1 (ko) | 1978-02-06 | 1981-10-27 | 삐에르 위브 | 이소부티라미드 유도체의 신규한 제조방법 |
EP0089153B1 (en) | 1982-03-17 | 1986-09-24 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
GB8607313D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
CA1339423C (en) | 1988-09-14 | 1997-09-02 | Yuji Ono | Pyridine compounds and pharmaceutical use thereof |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
HU207047B (en) | 1989-11-07 | 1993-03-01 | Richter Gedeon Vegyeszet | Process for producing new pyridine derivatives and pharmaceutical copositions comprising same |
US5364943A (en) | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
GB9021056D0 (en) | 1990-09-27 | 1990-11-07 | Pfizer Ltd | Antiarrhythmic agents |
GB9214120D0 (en) | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
WO1994003429A1 (en) | 1992-07-31 | 1994-02-17 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
US5387595A (en) | 1992-08-26 | 1995-02-07 | Merck & Co., Inc. | Alicyclic compounds as tachykinin receptor antagonists |
GB9305672D0 (en) | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
DE69428913T2 (de) | 1993-12-29 | 2002-05-29 | Merck Sharp & Dohme | Substituierte morpholinderivate und ihre verwendung als arzneimittel |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
JPH10501228A (ja) | 1994-06-06 | 1998-02-03 | ワーナー−ランバート・コンパニー | タキキニン(nk▲下1▼)受容体アンタゴニスト |
US6294537B1 (en) | 1995-03-17 | 2001-09-25 | Sanofi-Synthelabo | Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools |
ES2194937T3 (es) * | 1995-03-24 | 2003-12-01 | Takeda Chemical Industries Ltd | Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
CN1546470A (zh) | 1996-03-29 | 2004-11-17 | ������ҩ������˾ | 6-苯基吡啶-2-基胺衍生物及其药物组合物 |
AU4885097A (en) | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
NZ513322A (en) * | 1999-02-24 | 2004-07-30 | F | Phenyl- and pyridinyl derivatives |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
TR200302077T4 (tr) * | 1999-11-29 | 2004-01-21 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit |
-
2000
- 2000-02-15 EP EP03026298A patent/EP1394150B1/en not_active Expired - Lifetime
- 2000-02-15 PT PT03026298T patent/PT1394150E/pt unknown
- 2000-02-15 DE DE60014216T patent/DE60014216T2/de not_active Expired - Lifetime
- 2000-02-15 ES ES03026298T patent/ES2359235T3/es not_active Expired - Lifetime
- 2000-02-15 PT PT00102260T patent/PT1035115E/pt unknown
- 2000-02-15 DE DE60045564T patent/DE60045564D1/de not_active Expired - Lifetime
- 2000-02-15 AT AT00102260T patent/ATE277905T1/de active
- 2000-02-15 EP EP00102260A patent/EP1035115B1/en not_active Expired - Lifetime
- 2000-02-15 DK DK00102260T patent/DK1035115T3/da active
- 2000-02-15 SE SE00102260T patent/SE1035115T5/xx unknown
- 2000-02-15 DK DK03026298.4T patent/DK1394150T3/da active
- 2000-02-15 ES ES00102260T patent/ES2226622T3/es not_active Expired - Lifetime
- 2000-02-15 SI SI200030506T patent/SI1035115T1/xx unknown
- 2000-02-15 AT AT03026298T patent/ATE496032T1/de active
- 2000-02-18 PE PE2000000125A patent/PE20001467A1/es not_active IP Right Cessation
- 2000-02-18 GB GB0003908A patent/GB2347422A/en not_active Withdrawn
- 2000-02-18 NZ NZ502948A patent/NZ502948A/en not_active IP Right Cessation
- 2000-02-21 HU HU0000748A patent/HU227629B1/hu unknown
- 2000-02-21 IL IL134654A patent/IL134654A/en active Protection Beyond IP Right Term
- 2000-02-21 GE GEAP20005227A patent/GEP20022676B/en unknown
- 2000-02-21 CZ CZ20000609A patent/CZ300596B6/cs not_active IP Right Cessation
- 2000-02-22 IS IS5381A patent/IS2116B/is unknown
- 2000-02-22 RS RSP-2008/0562A patent/RS20080562A/sr unknown
- 2000-02-22 MY MYPI20000648A patent/MY123648A/en unknown
- 2000-02-22 UA UA2000021039A patent/UA71547C2/uk unknown
- 2000-02-22 GT GT200000017A patent/GT200000017A/es unknown
- 2000-02-22 MY MYPI20044751A patent/MY147451A/en unknown
- 2000-02-22 SK SK5052-2008A patent/SK287912B6/sk not_active IP Right Cessation
- 2000-02-22 JO JO200014A patent/JO2294B1/en active
- 2000-02-22 FR FR0002170A patent/FR2790473B1/fr not_active Expired - Fee Related
- 2000-02-22 PA PA20008491101A patent/PA8491101A1/es unknown
- 2000-02-22 SK SK235-2000A patent/SK287911B6/sk not_active IP Right Cessation
- 2000-02-22 DE DE10008042A patent/DE10008042A1/de not_active Withdrawn
- 2000-02-22 TN TNTNSN00032A patent/TNSN00032A1/fr unknown
- 2000-02-22 RS RS20080562A patent/RS53869B1/en unknown
- 2000-02-22 ME MEP-2009-57A patent/ME00593B/me unknown
- 2000-02-22 EG EG20000206A patent/EG23817A/xx active
- 2000-02-22 US US09/507,456 patent/US6297375B1/en not_active Expired - Lifetime
- 2000-02-22 RS YUP-95/00A patent/RS50194B/sr unknown
- 2000-02-22 AR ARP000100737A patent/AR029614A1/es active IP Right Grant
- 2000-02-23 CA CA2299139A patent/CA2299139C/en not_active Expired - Lifetime
- 2000-02-23 ZA ZA200000894A patent/ZA200000894B/xx unknown
- 2000-02-23 ES ES200000418A patent/ES2171109B2/es not_active Expired - Fee Related
- 2000-02-23 MA MA25913A patent/MA26722A1/fr unknown
- 2000-02-23 SV SV2000000024A patent/SV2002000024A/es active IP Right Grant
- 2000-02-23 KR KR10-2000-0008674A patent/KR100384904B1/ko active Protection Beyond IP Right Term
- 2000-02-23 NO NO20000885A patent/NO315554B1/no not_active IP Right Cessation
- 2000-02-23 CN CNB001024019A patent/CN1142144C/zh not_active Expired - Lifetime
- 2000-02-23 HR HR20000097A patent/HRP20000097B1/xx not_active IP Right Cessation
- 2000-02-23 EA EA200000155A patent/EA003673B1/ru active Protection Beyond IP Right Term
- 2000-02-23 SG SG200001033A patent/SG91856A1/en unknown
- 2000-02-23 BR BRPI0000908A patent/BRPI0000908B8/pt not_active IP Right Cessation
- 2000-02-23 IT IT2000MI000328A patent/IT1320763B1/it active
- 2000-02-24 TR TR2000/00520A patent/TR200000520A3/tr unknown
- 2000-02-24 JP JP2000047003A patent/JP3399900B2/ja not_active Expired - Lifetime
- 2000-02-24 PL PL338598A patent/PL217311B1/pl unknown
- 2000-02-24 OA OA1200000052A patent/OA11680A/fr unknown
- 2000-02-24 BG BG104187A patent/BG64554B1/bg unknown
- 2000-02-24 AU AU19468/00A patent/AU767048B2/en active Active
- 2000-02-25 TW TW089103387A patent/TWI288746B/zh not_active IP Right Cessation
-
2001
- 2001-03-12 HK HK01101744A patent/HK1031223A1/xx unknown
- 2001-07-10 US US09/901,982 patent/US6479483B2/en not_active Expired - Lifetime
-
2007
- 2007-09-24 AR ARP070104196A patent/AR062949A2/es active IP Right Grant
-
2008
- 2008-06-27 HR HRP20080306AA patent/HRP20080306B1/hr not_active IP Right Cessation
-
2009
- 2009-12-10 UY UY0001032314A patent/UY32314A/es not_active Application Discontinuation
-
2011
- 2011-02-10 CY CY20111100162T patent/CY1111317T1/el unknown
-
2015
- 2015-06-17 LU LU92745C patent/LU92745I2/xx unknown
- 2015-07-08 FR FR15C0049C patent/FR15C0049I2/fr active Active
- 2015-08-28 NL NL300758C patent/NL300758I2/nl unknown
- 2015-10-21 LT LTPA2015036C patent/LTC1035115I2/lt unknown
- 2015-10-29 BE BE2015C057C patent/BE2015C057I2/fr unknown
- 2015-10-29 CY CY2015042C patent/CY2015042I1/el unknown
- 2015-10-29 CY CY2015041C patent/CY2015041I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200000017A (es) | Procedimiento para la obtencion de derivados de 4-fenil-piridina. | |
CL2004000861A1 (es) | Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp | |
ES2054872T3 (es) | Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht. | |
GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
SV2002000357A (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb | |
ES2089056T3 (es) | Derivados de hidrazincarboxamida, un procedimiento para la produccion de los mismos, y usos de los mismos. | |
BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
UY26728A1 (es) | Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos | |
DE60025604D1 (de) | Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
ES2056105T3 (es) | Di-t-butilfenoles sustituidos. | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
ES2070253T3 (es) | Ciclohexanoles sustituidos utiles como agentes para el sistema nervioso central. | |
ES2132223T3 (es) | Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4. | |
UY26662A1 (es) | Compuestos que contienen benzamido-piperidina y compuestos relacionados. | |
ES2088388T3 (es) | Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal. | |
ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
AR006119A1 (es) | Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos | |
UY27023A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
UY28377A1 (es) | Agentes terapeuticos | |
UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
ES2182114T3 (es) | Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano. | |
ES2101012T3 (es) | Derivados de acidos guanidinoalquilo-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion. | |
PA8604101A1 (es) | Derivados de imidazol | |
ES2078455T3 (es) | 3-aril-4(3h)quinazolinonas antagonistas de cck y formulados farmaceuticos de las mismas. | |
ES2158996T3 (es) | Agonistas beta3 adrenergicos selectivos. |